[Case of pediatric chronic myeloid leukemia with bilateral visual loss onset].
BACKGROUND
Chronic myeloid leukemia (CML) during childhood is rare, and only been a few cases showed visual disturbances as an initial symptom. We report a pediatric CML case diagnosed by bilateral visual loss.


METHODS
An 11-year-old boy complained of visual loss in both eyes. His best corrected visual acuity was 0.5 in the right eye and 0.2 in the left. Fundus examination showed disc swelling, dilated and tortuous retinal veins and multiple elevated retinal lesions with hemorrhages of various size from one-forth to four disc diameters in both eyes. He was diagnosed as having CML by leucocytosis and systematic work-up including Philadelphia chromosome-positive, BCR-ABL kinase domain in peripheral blood and bone marrow. The ocular findings improved after treatment with hydroxyurea, leukocytaphresis and imatinib. His best corrected visual acuity improved to 0.7 in both eyes.


CONCLUSIONS
Recent leukemia therapy including imatinib is effective not only for ocular lesions but also to induce hematological remission in childhood CML.
Hara
Yusuke
Y
Division of Ophthalmology, Department of Visual Sciences, Nihon University School of Medicine, Tokyo, Japan. qqm798md@theia.ocn.ne.jp
Kamura
Yumi
Y
Oikawa
Aki
A
Shichino
Hiroyuki
H
Mugishima
Hideo
H
Goto
Hiroshi
H
D000970:Antineoplastic Agents / Q000627:therapeutic use; D001549:Benzamides; D014408:Biomarkers, Tumor / Q000097:blood; D002648:Child; D016044:Fusion Proteins, bcr-abl / Q000097:blood; D006801:Humans; D006918:Hydroxyurea / Q000627:therapeutic use; D000068877:Imatinib Mesylate; D007937:Leukapheresis; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000150:complications* / Q000175:diagnosis / Q000628:therapy*; D008297:Male; D010677:Philadelphia Chromosome; D010879:Piperazines / Q000627:therapeutic use; D011743:Pyrimidines / Q000627:therapeutic use; D012074:Remission Induction; D016896:Treatment Outcome; D015354:Vision, Low / Q000175:diagnosis / Q000209:etiology* / Q000473:pathology / Q000628:therapy*
D000970:Antineoplastic Agents; D001549:Benzamides; D014408:Biomarkers, Tumor; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D016044:Fusion Proteins, bcr-abl; D006918:Hydroxyurea